Geneticists have a better understanding of how prehistoric pairings unfolded, with new research suggesting they were mostly ...

As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

Scientists have identified how specific genetic changes function in cells to influence disease risk and other human health ...

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

For more than a century, Mendelian genetics has shaped how we think about inheritance: one gene, one trait. It is a model that still echoes through textbooks—and one that is increasingly reaching its ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Duckweed is the fastest-growing flowering plant, but new knowledge of duckweed genetics discovered by Adelaide University ...

Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities despite facing significant customer revenue loss.

Why do some people feel chills when listening to music, reading poetry, or viewing a powerful work of art, while others do ...